Novel targets for endometriosis-associated pain
article
OA: closed
CC0
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This paper identifies novel molecular targets associated with endometriosis-related pain.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (9)
- Dichloroacetate for the treatment of endometriosis-associated pain (EPiC1): a single-arm feasibility study via openalex
- Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia via openalex
- Reevaluating response and failure of medical treatment of endometriosis: a systematic review via openalex
- Repurposing dichloroacetate for the treatment of women with endometriosis via openalex
- Safety and efficacy of subcutaneous injection with HMI-115 versus placebo in endometriosis-associated pain in premenopausal women: a multicentre, double-blind, randomised, proof-of-concept phase 2 trial via openalex
- The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology via openalex
- W4234160457 via openalex
- W4413117461 via openalex
- W3039522688 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK